Lin and colleagues have recently described the development of phosphonate inhibitors of human ENO2, the enzyme that interconverts 2-phosphoglycerate (2-PG) to phosphoenolpyruvate (PEP) in glycolysis and gluconeogenesis, for the treatment of ENO1-/- GBM [5]. The gene discussed is ENO2; the disease is glioblastoma.